AstraZeneca India, a pharmaceutical company, announced on Friday that the Drugs Controller General of India had given the go-ahead to commercialise its medication for the treatment of breast cancer. In adults with early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy, the Drugs Controller General of India (DCGI) has approved Lynparza Continue Reading
